Sorafenib

Drug Profile

Sorafenib

Alternative Names: BAY 43-9006 Tosylate; BAY 54-9085; BAY-43-9006; Nexavar; Sorafenib tosilate; Sorafenib tosylate

Latest Information Update: 13 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Onyx Pharmaceuticals; University of Kentucky
  • Developer ACORN Research; Asan Medical Center; Bayer; Beth Israel Deaconess Medical Center; Charite of Berlin; Genentech; Indiana University School of Medicine; National Cancer Center (Korea); National Cancer Institute (USA); Onyx Pharmaceuticals; Oregon Health & Science University; Thomas Jefferson University; University of California, San Diego; University of Texas M. D. Anderson Cancer Center; Yale University
  • Class Amides; Antineoplastics; Benzenesulfonates; Chlorobenzenes; Pyridines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Fms-like tyrosine kinase 3 inhibitors; Mitogen-activated protein kinase inhibitors; Mitogen-activated protein kinase kinase inhibitors; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein b raf inhibitors; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Proto oncogene proteins c raf inhibitors; Raf kinase inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thyroid cancer; Liver cancer; Renal cell carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatocellular carcinoma; Renal cell carcinoma; Thyroid cancer
  • Phase II Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Gastric cancer; Glioma; Head and neck cancer; Myelodysplastic syndromes; Neurofibromatoses; Ovarian cancer; Portal hypertension; Soft tissue sarcoma
  • Phase I Acute promyelocytic leukaemia; Cancer; Neuroendocrine tumours; Pancreatic cancer; Solid tumours
  • Suspended Malignant melanoma; Prostate cancer
  • No development reported Colorectal cancer; Germ cell and embryonal neoplasms
  • Discontinued Breast cancer; Non-small cell lung cancer; Small cell lung cancer

Most Recent Events

  • 08 Sep 2017 Efficacy and adverse events data from a phase III trial in Renal cell carcinoma presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
  • 10 Aug 2017 NICE recommends sorafenib for routine use of some patients on NHS
  • 02 Jun 2017 Adverse events data from the phase III Decision trial in Thyroid cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top